SEC Form 4 · accession 0001209191-18-000388
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Mendlein
Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 2, 2018 · 7:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 370,382 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $3.80 | Jan 2, 2018 | A | 32,000 | A | — | Jan 2, 2028 | Common Stock | 32,000 | 32,000 | D |
Explanation of responses
- F1Includes 2,499 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on November 15, 2017.
- F2The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning February 2, 2018, such that this option will be fully exercisable on January 2, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors.